ONO Pharmaceutical USA
Presencia
ONO Pharmaceutical es una de las ...
ONO Pharmaceutical es una empresa que cotiza bajo el símbolo de cotización 4528 (JP).
ONO Pharmaceutical tiene presencia directa en 2 países.
Ejecutivos
Ver el organigrama con sus 3 ejecutivos principales
Biografías más buscadas en ONO Pharmaceutical USA
- Kunihiko Ito, President and Chief Executive Officer
- David Trexler, Chief Commercial Officer
- Thomas Lechner, Vice President, Medical Affairs
Crear su alerta
para seguir los movimientos de los ejecutivos en ONO Pharmaceutical USA.
Farmacia
ONO Pharmaceutical tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de ONO Pharmaceutical USA
- ONO PHARMA Announces Enrollment Is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL | ONO Pharma USA, Inc.
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University | ONO Pharma USA, Inc.
- Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins | ONO Pharma USA, Inc.
- ONO Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2023 | ONO Pharma USA, Inc.
- Support for Disasters Caused by the 2024 Noto Peninsula Earthquake | ONO Pharma USA, Inc.
- Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs | ONO Pharma USA, Inc.
- ONO Selected for the DJSI World Index and DJSI Asia Pacific Index for Four Straight Years | ONO Pharma USA, Inc.
- Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Ono Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein | ONO CORPORATEicon_search_whiteicon_close_wicon_search_g
- View more press releases Close
Redes sociales sobre ONO Pharmaceutical USA
- ONO Pharmaceutical USA en Wikipedia, Google News y Yahoo Finance
- ONO Pharmaceutical USA en LinkedIn, Twitter y YouTube
